Merck & Co., Inc. (MRK) Earnings Call Transcript & Summary

August 4, 2026

New York Stock Exchange US Health Care Pharmaceuticals earnings 60 min

What were the key takeaways from Merck & Co., Inc.'s August 4, 2026 earnings call?

In the second quarter of 2026, Merck & Co., Inc. reported revenues of $16.6 billion, representing a 5% increase year-over-year, driven by strong performance in Oncology and Animal Health. The company reported a loss of $0.13 per share, primarily due to a one-time charge of $2.31 per share from the acquisition of Terns Pharmaceuticals. Management raised full-year revenue guidance to a range of $66.3 billion to $67.3 billion, reflecting continued confidence in their product pipeline and market opportunities.

What topics did Merck & Co., Inc. cover?

  • Revenue Growth: Merck reported revenue of $16.6 billion for Q2 2026, a 5% increase year-over-year. Management noted, "we're also making substantial investments in the next generation of innovative medicines and vaccines," indicating a focus on future growth.
  • KEYTRUDA Performance: Sales of the KEYTRUDA family increased 4% to $8.4 billion, driven by strong uptake in earlier-stage cancers. Management stated, "We remain confident in the trajectory of KEYTRUDA QLEX adoption," suggesting sustained demand.
  • LIPFENDRA Approval: The FDA approved LIPFENDRA, the first oral PCSK9 inhibitor, which management described as a "major milestone" for cardiovascular treatment. This approval is expected to enhance Merck's position in the cardiometabolic market.
  • Acquisition of Terns Pharmaceuticals: Merck completed the acquisition of Terns Pharmaceuticals for $5.7 billion, which is expected to strengthen its hematology pipeline. Management emphasized this reflects their "continued focus on pursuing science-driven business development."
  • Guidance Update: Management raised full-year revenue guidance to between $66.3 billion and $67.3 billion, indicating confidence in achieving growth targets. They noted this guidance includes a positive impact from foreign exchange of approximately 1%.

What were Merck & Co., Inc.'s August 4, 2026 results?

  • Revenue: $16.6 billion
  • Full Year Revenue Guidance: $66.3 billion to $67.3 billion
  • Gross Margin: 81.1% (decrease of 1.1 percentage points)
  • Operating Expenses: $12.6 billion
  • Tax Provision: $882 million
  • Other Expense: $290 million (primarily reflecting financing costs related to recent business development transactions)

Merck's strong Q2 results and raised guidance indicate a robust outlook, supported by new product launches and a solid pipeline. The company's strategic focus on innovation and disciplined capital allocation positions it well for future growth, though analysts remain cautious about the sustainability of this growth amid increasing competition and market dynamics.

Earnings Call Speaker Segments

Peter Dannenbaum

executive
#1

Thanks, Shirley, and good morning to all of you. It's a pleasure to welcome everyone to the conference call for the second quarter of 2026, held by Merck & Company, Inc., based in Rahway, New Jersey, U.S. Joining us on today's call are Rob Davis, our Chairman and Chief Executive Officer, Caroline Litchfield, our Chief Financial Officer, and Dr. Dean Li, President of Research Labs. Before we begin, I want to note that our GAAP results include items such as acquisition-related charges, restructuring costs, and certain other items, all of which have been excluded from our non-GAAP results. A reconciliation of these figures can be found in our press release. I should also remind everyone that certain statements we make today could be deemed forward-looking statements under the Safe Harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. These statements reflect the current beliefs of our company's management and carry significant risks and uncertainties. Should our underlying assumptions turn out to be inaccurate, or should uncertainties come to pass, actual results could differ materially from those described in the forward-looking statements. Our SEC filings, including Item 1A in the 2025 10-K, list certain risk factors and cautionary statements that could cause the company's actual results to differ materially from those projected in any forward-looking statements we make this morning. Merck & Company, Inc., Rahway, New Jersey, U.S., assumes no obligation to publicly update any forward-looking statements. A slide presentation will accompany our speakers' prepared remarks during today's call. Those slides, together with the earnings release, today's prepared remarks, and our SEC filings, are all available in the investor relations section of our company's website; with that, I'll hand the call over to Rob.

Rob Davis

executive
#2

Thank you, Peter. Good morning, and thank you for being with us on today's call. My satisfaction remains high regarding the considerable strides we are taking throughout our business, propelled by solid execution, expanding contributions from newly launched products, and the ongoing progress of the next wave of innovation emerging from our pipeline. Earlier this year, we shared details about more than $70 billion in commercial opportunity available to us from over 20 new products that we anticipate will reshape our portfolio and, in numerous instances, the practice of medicine, while also driving growth well into the next decade. We also laid out a set of clinical milestones representing key events meant to substantially de-risk this opportunity. From that point onward, we've made substantial headway on that objective, and a number of significant validation milestones came in ahead of schedule. That momentum only reinforces the strong conviction I already held about where this company is headed and our ability to deliver lasting value to both patients and shareholders. Turning to how we performed in the second quarter, our revenue came in at $16.6 billion, which shows continued momentum in oncology and animal health as well as an expanding boost from products we've recently brought to market. The key thing is that while we're serving patients right now, we're also putting considerable resources behind the next wave of breakthrough treatments and vaccines. Our confidence in the guidance for the rest of the year hasn't wavered, and Caroline is going to walk through those details in a few moments. We hit a number of key milestones on the clinical and regulatory fronts as well. Starting with cardiometabolic: the FDA gave the green light to LIPFENDRA — the first and only oral PCSK9 inhibitor, indicated alongside diet and exercise to help lower LDL cholesterol in adults who have hypercholesterolemia. Getting to work with the FDA through the Commissioner's National Priority Voucher process was a pleasure, and it let us deliver this significant new treatment option to patients faster than usual. Now we're eager to open up wide access for patients, so we can help tackle elevated LDL-C, which stands as a leading modifiable risk factor for cardiovascular disease. Over in oncology, a handful of approvals came through, highlighting how KEYTRUDA keeps making a difference and how solid our oncology portfolio remains. And at ASCO, the data we shared was encouraging, offering further evidence of KEYTRUDA's durability. During our Investor Event, we showcased progress on several promising pipeline candidates. That included initial favorable top-line data from the large phase III worldwide clinical development effort for sac-TMT, our Trop-2-targeted antibody drug conjugate, in specific individuals with advanced or recurrent endometrial cancer. On the immunology side, we reported favorable phase III top-line induction findings for tulisokibart in certain patients with ulcerative colitis, and we are beginning to observe the first among many further trial results, which strengthens our belief in what this program could achieve. During the AIDS 2026 Congress that took place last week, we presented strong results from our extensive HIV pipeline. Those results included data on islatravir paired with lenacapavir, a combination that could become the very first once-weekly oral HIV treatment for adults whose virus is virologically suppressed. We're thrilled to re-enter the HIV space with a range of significant therapies, among them the recently launched Edvinzo. Ahead of the meeting's start, we laid out our initial access strategy for alimatravir, an oral HIV PrEP candidate dosed once a month that we're currently studying, which has now reached phase III trials. This underscores our dedication to enabling broad, sustainable access to this candidate should it receive approval. We also keep strengthening our portfolio by way of disciplined business development. In the quarter, we finished buying Terns Pharmaceuticals, which brought in MK-4208, a novel therapy with the potential to be best-in-class for certain patients who have chronic myeloid leukemia. That deal bolsters our hematology pipeline, contributes one more promising late-stage growth opportunity, and shows our ongoing emphasis on science-driven business development that can help patients and boost long-term shareholder value; this quarter represents my fifth year as CEO, and when I look back at what our leadership team pledged in 2021, the strategy we set was plain: get the most out of KEYTRUDA's transformative potential, broaden, deepen, and lengthen our oncology leadership, deliver new growth drivers in additional therapeutic areas, and carry forward Merck's mission of harnessing leading-edge science to save and improve lives worldwide. I'm proud that today we're carrying out that strategy effectively. Year after year, we make meaningful headway in constructing a more solid foundation for what lies ahead; we're widening and diversifying our pipeline, moving forward several potential blockbusters, and hitting clinical, regulatory, and commercial milestones that will help patients and improve our long-term growth trajectory. In my view, Merck stands substantially stronger, more diversified, and better set up for sustainable growth than was the case merely five years back. More work still lies ahead, yet my confidence in Merck's future keeps growing, especially given how quickly clinical and regulatory events are now unfolding. Our assurance is grounded in the strength of our scientific work, our careful approach to deploying capital—including through business development—and the dedication of our employees around the globe, who work each day on behalf of patients. On this substantial progress, I want to extend special thanks to our worldwide team, recognizing their commitment and their delivery for patients, for shareholders, and for everyone with a stake in our company. Caroline, over to you.

Caroline Litchfield

executive
#3

Thanks, Rob. Morning, everyone. During the quarter we achieved growth, powered by ongoing momentum in oncology and animal health, plus rising contributions from a wide and impressive set of new products spanning many therapeutic areas. Solid execution on both the commercial and operational fronts keeps fueling near-term results, even as we put money into our exceptional pipeline to build long-term value for patients, customers, and shareholders. Now to our second quarter results. Revenue for the whole company came in at $16.6 billion, up 5%, or 4% when you strip out foreign exchange effects. These revenue remarks will all be on an ex exchange basis; within oncology, sales for the KEYTRUDA family of products, comprising KEYTRUDA and KEYTRUDA QLEX, rose 4% to $8.4 billion, with worldwide growth fueled by strong uptake in earlier stage cancers and sustained robust demand across metastatic indications. Robust utilization in tumors that mainly affect women, such as breast and cervical cancers, plus greater use of KEYTRUDA alongside PADCEV in locally advanced or metastatic urothelial cancer, were major growth drivers. KEYTRUDA QLEX sales reached $463 million. Physician and patient adoption has climbed since the permanent J-code was put in place in April. As we anticipated, early use has been mostly among patients either on monotherapy or on combination with an oral agent; our confidence in how KEYTRUDA QLEX adoption will progress remains strong. Our wider oncology portfolio posted yet another quarter of robust growth. WELIREG sales climbed 67% to $271 million, powered by continued uptake from international launches and greater use among certain U.S. patients with previously treated advanced renal cell carcinoma. We're thrilled that certain patients with earlier stage renal cell carcinoma might benefit from adjuvant treatment with WELIREG after the recent FDA approval of LITESPARK-022. In vaccines and infectious diseases, GARDASIL sales hit $1.2 billion, a rise of 3%. International market sales grew 6%, while the U.S. was approximately flat, since weaker demand and the timing of CDC purchases were mostly offset by price. Within pneumococcal, CAPVAXIVE sales totaled $184 million, a 40% increase. Growth came mainly from uptake driven by ongoing launches in certain international markets, plus stronger U.S. demand. In HIV, we're happy to have launched Edvinzo, our once-daily oral two-drug single-tablet regimen of doravirine and islatravir for certain virologically suppressed adults; early progress on access and reimbursement has been encouraging, and we look forward to widening access over time. In cardiometabolic and respiratory, WINREVAIR global sales reached $588 million, up 75%, reflecting continued strong demand from adults with pulmonary arterial hypertension. In the U.S., we made further progress, with more than 1,800 new patients having gotten a prescription, and a higher proportion of patients whose background therapies exclude a prostacyclin. Beyond the U.S., we keep advancing with ongoing launches. Ohtuvayre sales were $204 million, reflecting sustained prescription demand from patients with COPD, along with a benefit from the timing of specialty pharmacy purchases. Our animal health segment turned in yet another quarter of strong growth, posting a 5% rise in sales. Livestock revenue climbed 6%, fueled by stronger demand for ruminant and poultry offerings. Companion animal sales were up 5%, thanks to new product introductions. I'll take you through the rest of the P&L now, and everything I say will be on a non-GAAP basis. Gross margin came in at 81.1%, down 1.1 percentage points, largely driven by higher inventory reserves. Operating expenses rose to $12.6 billion. During the quarter we recorded a $5.7 billion charge tied to acquiring Terns Pharmaceuticals, versus a $200 million business development charge in the prior year. If you set those charges aside, operating expenses were up 7%, reflecting greater investments behind our launches and our strong early and late-phase pipeline, partly offset by gains from our multi-year optimization program and recognition of a portion of the external funding for sac-TMT development. Other expense climbed to $290 million, mainly due to financing costs from recent business development transactions. Our tax provision totaled $882 million. Because of the non-tax-deductible one-time charge for Terns, our tax rate reached 160.3%. All told, we posted a loss of $0.13 per share, which includes a one-time charge of $2.31 per share stemming from the Terns acquisition. Now let's move to our 2026 non-GAAP guidance. We've raised and narrowed our full-year revenue guidance range to between $66.3 billion and $67.3 billion, which represents growth of 2%-4%, including an approximate one percentage point positive impact from foreign exchange using mid-July rates. Gross margin is now assumed to be approximately 81%, reflecting higher inventory reserves. Operating expenses should land between $42 billion and $42.7 billion; that range includes $5.8 billion for the upfront charge for Terns and investment to advance MK-4208. This guidance doesn't assume any additional significant potential business development transactions. Other expense, which now incorporates the financing costs for Terns, is expected to be approximately $1.4 billion. We now expect a full-year tax rate between 35% and 36%, which reflects the non-tax-deductible one-time charge for Terns. We assume approximately 2.48 billion shares outstanding. Putting it all together, we expect EPS of $2.66-$2.76, with a midpoint of $2.71, including an approximate $0.15 positive impact from foreign exchange using mid-July rates. This range also includes an upfront charge of $2.31 per share related to the acquisition of Terns, as well as approximately $0.12 per share of ongoing costs to advance MK-4208 and finance the transaction. As you think about your models, there are a few things to keep in mind for the second half of the year. First, on OHTUVAYRE. We remain excited about OHTUVAYRE's strong clinical profile and look forward to achieving its multi-billion-dollar commercial potential in the coming years. During Q3, sales will take a hit from the reversal of specialty pharmacy buying that happened in Q2. We're still putting money behind our sales force and promotion efforts so we can connect with more physicians and patients across the U.S. On top of that, we're collaborating with our specialty pharmacies to make things better for patients. Our expectation is that these steps will drive faster growth in 2027. We think total U.S. KEYTRUDA growth compared with a year earlier will slow down, since we're getting closer to peak penetration in a number of key indications. Also, just to remind everyone, the timing of wholesaler purchases gave us a benefit of roughly $250 million in Q3 of 2025, and that won't happen again this year. When it comes to BRIDION, U.S. sales should fall more slowly than we'd previously thought, because generic competition has been lighter than expected. Lastly, other revenue for the back half of 2026 should come in significantly above the back half of 2025. That lift comes mainly from our revenue hedging program, plus a milestone payment we expect to receive in Q4 tied to an out-license agreement. Now on to capital allocation, where our approach hasn't changed. We'll keep giving priority to investments that fuel near- and long-term growth, such as our new product launches and our strong pipeline. We're staying dedicated to the dividend, with the aim of raising it as time goes on. Business development is still a top priority, and within a solid investment-grade credit rating, we retain the capacity to go after further science-driven deals that create value. We're on track for about $3 billion of share repurchases this year, consistent with what we said before. To wrap up, as we head into the back half of the year, our confidence in the business outlook holds, backed by worldwide demand for our innovative medicines and vaccines, including the many new products we've launched. Our portfolio transformation is in progress, and we're positioned well to create value for patients, customers, and shareholders both now and in the future. With that, I'll hand the call over to Dean.

Dean Li

executive
#4

Thank you, Caroline, and good morning to all of you. Several notable regulatory and clinical milestones defined our second quarter. In my remarks today, I'll share updates across cardiometabolic disease, HIV, infectious disease, immunology, and oncology. Then I'll wrap up with the key milestones ahead as we set our sights on the back half of 2026. Starting with cardiometabolic disease. As Rob noted, we just secured FDA approval for LIPFENDRA, which is the first oral PCSK9 inhibitor to be approved. Data from the CORALreef Lipids trial demonstrated that LIPFENDRA lowers LDL cholesterol with strong efficacy, achieving as much as a 60% reduction on top of a statin. Updated U.S. dyslipidemia management guidelines issued earlier this year by the American College of Cardiology and American Heart Association acknowledged that atherosclerotic cardiovascular disease continues to rank as the top cause of morbidity and mortality, and emphasized that earlier intervention is needed to help cut lifelong risk stemming from prolonged exposure to elevated lipoproteins. Those guidelines also reinstated and tightened LDL cholesterol treatment targets, among them a goal below 55 milligrams per deciliter for people with ASCVD facing very high risk of ASCVD events. Securing approval for LIPFENDRA represents a significant step in our push to make PCSK9 inhibition available through a convenient once-daily oral option. Because it is an oral macrocyclic peptide, LIPFENDRA could broaden global access to this therapeutic approach. Reviews are additionally in progress in the European Union and China. Beyond that, we're moving forward with combination strategies intended to drive LDL cholesterol even lower and to address other ASCVD risk factors. Ongoing studies will support development of two possible fixed-dose combinations built around LIPFENDRA — one paired with rosuvastatin, and the other with MK-7262, our oral Lp inhibitor. Now to HIV. Yesterday we held an Investor Event centered on our HIV program, which included new data shared at AIDS 2026. Edvinzo serves as the cornerstone of what we expect will be a sequence of novel additions to this field. Our late-stage pipeline is designed to tackle unmet needs among those living with HIV or at risk of it, through innovative oral choices — among them two once-weekly treatment regimens and a monthly oral option for pre-exposure prophylaxis; together with Gilead, we reported full results from the phase III ISLAND 1 and 2 trials, which assessed the investigational oral once-weekly regimen combining islatravir and Gilead's lenacapavir. In both studies, virologic suppression was maintained among adults living with HIV who transitioned from a daily standard of care. These findings back the potential for ISL/LEN to be the first approved oral once-weekly treatment regimen for adults whose HIV is virologically suppressed. We also presented results from a phase IIb study of the investigational oral once-weekly pairing of islatravir and ulonivirine, an internally developed investigational non-nucleoside reverse transcriptase inhibitor, in adults with virologically suppressed HIV. Given these findings, we intend to move ISL+ULO into phase III studies for people living with HIV who have not previously been treated as well as those with prior treatment experience. In addition, we're continuing to assess alimatravir, our monthly oral HIV PrEP option, in two phase III studies that are expected to read out next year. Then, in the infectious disease space, we're making headway on our phase III trial of MK-1406, an investigational antiviral that acts for a long duration and is not limited by strain, intended to stop influenza. Patient enrollment wrapped up in the Southern Hemisphere. We've now got plans set to carry the trial through another Northern Hemisphere flu season, which will bolster our worldwide regulatory submissions; we're still on schedule for a possible approval in 2029. Shifting over to immunology, tulisokibart turned out to be the initial anti-TL1A monoclonal antibody that showed favorable outcomes in a phase III study. Back in June, we gave a report on the induction-only portion of the ATLAS-UC trial. Among individuals suffering from moderately to severely active ulcerative colitis, tulisokibart achieved the primary goal of clinical remission, along with important secondary goals, and we found no fresh safety issues. We're eager for the forthcoming data from the bigger induction and maintenance trial, which, alongside the induction-only trial, would serve as the foundation for a regulatory submission and will be shown at a future scientific congress; these results bolster the promise of going after TL1A to help tackle immunofibrosis, a major factor driving disease advancement across numerous immune-mediated inflammatory conditions. We've pushed forward a wide-ranging phase II development effort to dig deeper into this idea, and we now have data from 2 of those trials. In SSc-ILD, the trial fell short of its primary goal. In hidradenitis suppurativa, we're happy to report that the trial hit its primary and important secondary goals. Findings will be released at the appropriate time. Last but not least, in oncology, KEYTRUDA keeps producing strong clinical evidence and regulatory clearances, even in earlier stages of the disease. Not long ago, following the approval of KEYNOTE-905, the FDA gave the green light to a broader indication for KEYTRUDA and KEYTRUDA QLEX, both paired with PADCEV as treatment before and after surgery for adults who have muscle-invasive bladder cancer, drawing on data from KEYNOTE-B15. This regimen is now enhanced no matter cisplatin eligibility and stands as the first and only perioperative immunotherapy plus ADC regimen to prolong survival for such patients; we're also glad that the FDA lately cleared KEYTRUDA and KEYTRUDA QLEX together with WELIREG for adjuvant treatment of specific patients with clear cell renal cell carcinoma, based on the LITESPARK-022 study. This represents WELIREG's debut approval in earlier-stage disease and lifts the overall count of earlier-stage indications for KEYTRUDA-based regimens to 13; in June, during our ASCO Investor Event, we provided updates spanning our wide and varied oncology portfolio; we additionally pointed to a string of pivotal readouts anticipated in the coming years; we're now starting to witness the first of those milestones come to fruition with the news of positive phase III data from our worldwide TroFuse development program assessing sac-TMT; in TroFuse-005, sac-TMT showed a statistically significant and clinically meaningful boost in both overall survival and progression-free survival compared to chemotherapy in specific patients with advanced or recurrent endometrial cancer. We intend to use the National Priority Review voucher for sac-TMT for our submission in endometrial cancer. These findings mark the first readout from our worldwide TroFuse program, encompassing 17 phase III studies. We deliberately built the TroFuse program to chase two things at once: chances to be first to market, where sac-TMT could take early leadership, and indications in breast cancer along with non-small cell lung cancer, where novel development approaches are possible. Findings coming out of our partner Kelun's program studying sac-TMT in China keep shaping this worldwide push. Encouraging data from OptiTROP-Lung05 and, more lately, OptiTROP-Lung06 make us even more confident about what this differentiated Trop-2-directed ADC could do. To wrap up, we see a packed back half of the year ahead, full of events and milestones, among them work in cardiometabolic and respiratory areas, plus the September 21st PDUFA date for WINREVAIR, seeking a label update grounded in the Phase III HYPERION study. On the immunology side for tulisokibart, there's the second readout from the ATLAS-UC trial, along with presentation of Phase II HS study data. Turning to ophthalmology, we have Phase III PRUNELLA study data for remigromig, which is also called MK-3000, our novel WNT agonist under evaluation in diabetic macular edema patients. And last, in oncology, possible approvals for WELIREG plus LENVIMA in advanced renal cell carcinoma, and for I-DXd in extensive stage small cell lung cancer, plus data presentations spanning our wide oncology portfolio, among them detailed Phase III TroFuse-005 study results. Please save the date for the evening of Monday, October 26th, when we'll hold an Investor Event at the European Society for Medical Oncology in Madrid. I'm eager to share more updates on how we're progressing. At this point I'll hand the call back to Peter.

Peter Dannenbaum

executive
#5

Thanks, Dean. Shirley, let's open it up for questions now. We'd ask that analysts please keep to a single question today, so that we're able to reach as many people asking questions as possible within the time available. Thanks.

Akash Tewari

analyst
#6

Thanks a lot. Dean, in the past you said that for first-line and TLC, a biomarker strategy would be the correct path. When it comes to sac-TMT, the OptiTROP-Lung05 and 06 results showed us a signal no matter what the PD-L1 expression was. How likely is it that we might get a broad sac-TMT plus pembro study pitted directly against KEYNOTE-189? And would it be accurate to say that for first-line lung, we could end up seeing sac-TMT combinations alongside pembro as well as a PD-1/VEGF? Thanks.

Dean Li

executive
#7

The short version from me is that every one of those is a yes. Let me pull back for a moment: regarding sac-TMT, as we've told you, we regard it as a cornerstone ADC. It is a Trop-2 ADC, and it comes with a novel linker along with a payload. As we laid out in the prepared remarks, we divided the phase III effort into 13 first mover, targeting indications where we believed we could get there first. In fact, our hope is that TroFuse-005 endometrial provides validation for that approach. As we've mentioned, we've been in discussions with the administration's FDA, and this is the candidate that will be pursuing National Priority Vouchers. When it comes to breast and lung, we've said differentiation is necessary because of the other Trop-2 ADCs out there. As you note, the Kelun OptiTROP-Lung05/06 gives us substantial confidence in the target, and in hitting it throughout the entire PD-L1 spectrum. Yes, we intend to rethink KEYNOTE-189, which consists of KEYTRUDA plus chemo, and at this point sac-TMT serves as an ADC, functioning as a next-gen chemo. I really believe we will be extremely thoughtful about the IO agent and about the circumstances for using KEYTRUDA versus using other agents, for instance MK-2010. As you can probably guess, we're pushing MK-2010 forward; keeping that in mind, we're proceeding at a rapid pace when it comes to launching trials — certain ones for signal finding, certain ones for dose and scheduling work aimed at optimizing with novel agents; we're pushing ahead with trials capable of moving from a phase II into phase III without interruption.

Peter Dannenbaum

executive
#8

Great. Thank you, Akash. Next question, please.

Umer Raffat

analyst
#9

Hello, everyone. I appreciate the chance to ask. Dean, congratulations on the HS trial news regarding TL1A. I'm simply reasoning through this aloud. As we move into these additional indications, how much of the effect we are observing with these TL1A agents goes past what a TNF would have led us to anticipate? I'm certain you understand my perspective here. Thank you.

Dean Li

executive
#10

Yes. Many thanks. To take a slight step backward, the way the question is framed reflects the reality that TL1A belongs to the TNF super family. These TNF drugs have proven quite valuable; they've been developed further. Combining them frequently creates difficulties due to their safety signal. Regarding what we've observed up to now, obviously, when immunology comes to mind, three categories come to mind. You think of GI, you think of derm, and you think of rheumatology. Within GI, obviously, we're quite keen to advance in ulcerative colitis and Crohn's disease, and we're very keen to see the remaining portion of the UC study. On the derm side, we have it in HS, and I believe that matters, along with having psoriatic arthritis. I think the favorable result in HS boosts our confidence in the derm opportunities for this drug. That's the area we're examining. I continue to believe that in the rheum area, which is, say, RA, and to some extent, psoriatic arthritis, we'll need to see how that unfolds once the data arrives. I can simply share, for instance, that for rheumatoid arthritis, we possess very clear biomarker data indicating we ought to pursue TL1A. Obviously, in a condition such as rheumatoid arthritis, there are animal models in preclinical settings where you can estimate your activity, and we have that data, which provides the strength to proceed in rheumatoid arthritis.

Peter Dannenbaum

executive
#11

Excellent. Thank you, Umer. Let's take the following question.

Terence Flynn

analyst
#12

Thanks for fielding this. Mine has two parts. Dean, I was hoping you might walk us through, before we get the AstraZeneca readout, the AVANZAR readout, what aspects of that dataset would interest you most, and what they'd mean for how you're developing sac-TMT. And then, whatever you're able to share — I realize this is a Kelun trial — regarding OptiTROP-Lung06, specifically how the control arm performed there, any thoughts? Thanks.

Dean Li

executive
#13

Yes. I'll address the second one first. Kelun is a terrific partner. The data we're shown is extremely granular, and what they've shared leaves us quite at ease, and it makes us highly confident as we proceed. Worth noting that certain findings we reviewed are the reason we, for instance, acted swiftly on endometrial; we hold substantial trust in the way they conduct their trials and in their data. I've lost the first part once more.

Peter Dannenbaum

executive
#14

AVANZAR.

Dean Li

executive
#15

AVANZAR. What matters most here, I believe, is that with AVANZAR we are still awaiting the data to come out. Our aim is to understand how it performs across the entire patient population, and how it performs when tied to a biomarker-based selection. From that, we'll get some sense of how to move our own program ahead and whether a biomarker is necessary. A biomarker is always an option, yet needing one isn't guaranteed. Beyond that, there's the question of how we pursue development alongside a strong PD-1 such as KEYTRUDA, or if instead we ought to push it forward with a strong PD-1 VEGF.

Peter Dannenbaum

executive
#16

Excellent. Thank you, Terence. Let's take the next question.

Michael Yee

analyst
#17

Thanks a lot. Regarding TL1A, I have a question with two parts. You reported one positive phase III trial in UC, yet not much detail was provided. Given that the second study is still to come, how should we frame the profile in ulcerative colitis? And then, everything is supposedly centered on fibrosis, but the SSc study did not come out positive today, so how does that shift our view regarding Crohn's and that fibrosis opportunity? Thank you.

Dean Li

executive
#18

Yes. I really appreciate that question. With respect to the tulisokibart study 2, we are quite keen to see study 1, since the two together will form the package we submit to the FDA, and we look forward to that readout as we move it ahead. Once more, in Crohn's disease, a clear signal exists — a clear signal coming not only from us, but from others as well — and the question is what we will observe in phase III. We are very interested in pushing those forward. You can examine some of the derm in the room indications I mentioned. Those will likewise include a fibrosis component. As for SSc-ILD, let me just step back. I am not aware of any anti-cytokine that has succeeded; this was a bold move to push that ahead. It is a challenging and refractory disease; we observe no safety concerns, and I will tell you that when we publish that data, as you can imagine we will, I will look very carefully at the placebo arm. If I find no progression in the placebo arm, it is an SSc-ILD; if I have no progression in the placebo arm, the chances that I can demonstrate benefit in a treatment arm become much harder. I would not discard the immunofibrosis based on the SSc-ILD study failing to read out positive in the specific patient population we enrolled.

Peter Dannenbaum

executive
#19

Thank you, Michael. Shirley, could we take the following question?

Geoff Meacham

analyst
#20

Hi there, everybody. I really appreciate you taking my question. Dean, regarding the LIPFENDRA launch, I'd like to know how your team sees the speed of perhaps the first access. I wasn't certain what the proper reimbursement assumption should be, or whether you believe the OUTCOMES trial might be required more as a commercial inflection point. Thanks.

Dean Li

executive
#21

If it's all right with you, let me hand the commercial portion over to Rob, and after that I can address whatever else is asked from the science side.

Rob Davis

executive
#22

Appreciate that, Geoff. Taking a step back, what I'd say is that thus far, the results have us feeling quite encouraged. As you're aware, the label is out there. It's a very clean label, and we're quite confident in it; given that we can achieve LDL reductions of as much as 60%, my belief is this will be a treatment that matters. Since the approval was announced, we've been getting a lot of strong interest from both physicians and patients. Orders started coming in last week, and we anticipate having product available at pharmacies before long. From the standpoint of access, on the whole, I'd say our position is fairly solid. Keep in mind, we deliberately structured things — through our pricing and our approach — to aim for broad access; even so, we recognize that establishing that access will require time. Our expectation is that the initial pace won't be especially quick, but over the longer term, we still anticipate this becoming a clear blockbuster opportunity down the road. I'll hand it to Dean to address the wider question from the scientific angle.

Dean Li

executive
#23

I should point out that you'll frequently hear people talk about the FDA under this particular administration. From what we've seen in our own discussions with the agency during this administration, they were eager to have LIPFENDRA serve as a flagship illustration of the priority review objectives they were pursuing. When it comes to the programs included in that priority review, most of them address just a single pillar of their overall goals; they made it very plain to us that they expect us to address every one of those pillars; what those pillars involve is going after a public health crisis, delivering an innovative breakthrough, and meeting a substantial unmet need, particularly within chronic disease, which stands as a pillar of this HHS. They left no doubt that they want onshoring along with supply chain and resilience here in the U.S., and they showed considerable interest in accessibility as it relates to broadening accessibility. Those five pillars represent what the FDA and our company are hurrying to accomplish as we bring this significant product to market.

Peter Dannenbaum

executive
#24

Excellent. Thank you, Geoff. Could we take the next question?

Chris Schott

analyst
#25

Thanks a lot for taking it. Given how much the pipeline has been de-risked over the last twelve months, I'm wondering whether you can share any directional perspective or fresh details about how Merck's earnings might trend as we work through the KEYTRUDA loss of exclusivity. I realize the company's emphasis is on getting back to growth by the early 2030s, but I'd still like to hear your thinking on what that in-between stretch for earnings might look like — say, from 2028 up to the early 2030s. Many thanks.

Rob Davis

executive
#26

Sure, Chris, I appreciate the question. During earlier discussions, we've expressed strong satisfaction with how things are going on the more than 20 items in our pipeline, representing $70 billion in commercial potential. We're already witnessing significant clinical risk reduction occurring more quickly than anticipated, along with solid, successful market entries for the therapies already introduced. Looking at where we stand right now, our confidence remains high, just as I've mentioned before. We regard the loss-of-exclusivity phase as something like a slope rather than a precipice. Our perspective hasn't shifted at all. My expectation is that you'll observe a modest decline followed by a swift rebound into expansion. To put it plainly, when you set risk aside, our goal remains expansion throughout this period. Additional effort is still required to make that happen, yet we're putting in the work to reach it. Sitting here at this moment, my confidence in our current position and the strides we're taking is quite high. There's always room for further improvement, but the cards we're holding at present leave me feeling optimistic.

Peter Dannenbaum

executive
#27

Excellent. Appreciate it, Chris. Could we take the following question?

Courtney Breen

analyst
#28

Hey everyone, we really appreciate you taking the question today. I have just one regarding LIPFENDRA, building on what was said about fixed dose combinations. You brought up rosuvastatin as well as your own Lp(a). Especially for rosuvastatin, I'd be curious to learn a bit about how you approach deciding which dose to use. Is it only intended for patients requiring additional escalation after reaching 40 mg, given that more adverse events occur at that point? And then as a second part, are you exploring additional combinations going forward? We've heard from peers about GLP-1 combinations alongside the PCSK9s, so I wanted to know whether you're still moving forward with or evaluating that opportunity. Last thing, we haven't yet seen it appear on TrumpRx. I'm just curious when that access channel is expected to start becoming available. Many thanks.

Dean Li

executive
#29

How about I hand TrumpRx over to Rob, and then I'll address the remaining ones?

Rob Davis

executive
#30

Yeah, we're really enthusiastic about what's ahead, as you're aware, under the MFN agreement we made, we committed to placing LIPFENDRA on TrumpRx. Those preparations are in motion. We're obviously focused on getting the initial launch underway, and once that's rolling, we'll have it up on TrumpRx. We'll share more regarding timing down the road.

Dean Li

executive
#31

When it comes to your questions about combinations, I appreciate that. At this point, we have an oral PCSK9, and it was created using what we learned from the antibodies, and we've managed to get LDL cholesterol reductions of as much as 60%. Our hope is that when paired with rosuvastatin, we'd show it across every dose — that combo — and we believe we could reach as high as 80%. Should we hit 80% with a combination, that would be a great day for medicine. That's roughly how we view the rosuvastatin piece; as for Lp, we'll need to find out what Lp truly does when it comes to the reduction. Our hope is that for a patient with elevated Lp, our combination could deliver CVOT outcomes unlike anything seen before in that context. Turning to GLP, we've concentrated — and stated that we're concentrating — on oral combinations. Combining GLP and PCSK9 is clearly possible. Something we're quite mindful of is that with the GLPs, you use step-up dosing. Nausea and vomiting occur frequently. We can pair GLP with PCSK9, though as of now we haven't announced on the clinical trials website that this is a combination we're actively pursuing.

Peter Dannenbaum

executive
#32

Excellent. Thank you, Courtney. Let's take the next one.

Jason Gerberry

analyst
#33

Hi, everyone. Appreciate you fielding my questions. I have one more about LIPFENDRA. In your view, what does the chance look like for switching patients from injectable PCSK9s compared with where most of the opportunity sits, among PCSK9-naive patients? Something we have observed, at least regarding injectable PCSK9, when compared with statins, is fairly limited uptake in primary care. With an oral option now available, how do you expect that to affect the dynamics of access and adoption in primary care? Thanks.

Rob Davis

executive
#34

Yes. Thank you for asking. We have stated repeatedly that our approach in this market is not centered on capturing share from injectable PCSK9s. At present, injectables reach only around 5% or less of the overall market. Here in the U.S. today, we have 30 million individuals on lipid-lowering therapies who still are not at recommended LDL levels, plus even more who receive no treatment. The opportunity in front of us is considerably larger. What drives us is growing the market and helping people recognize that cardiovascular disease remains the number 1 silent killer in the U.S. We now have a medicine that lowers LDL, one of the primary drivers of arteriosclerosis, which leads to that cardiovascular death by as much as 60% when added on top of statins. Anyone at risk ought to be taking one of these therapies. Our aim is to grow, build, and educate the market, and that is what we are pursuing alongside our work on the guidelines. Naturally, all of this takes time, since there is inertia we must push against. If we succeed, this honestly ought to lift the water for all boats rather than being a situation where we simply take share.

Dean Li

executive
#35

So, regarding that inertia — take, for instance, the American Heart Association along with the American College of Cardiology and several other major organizations; they recognize this inertia exists, and that's why they went ahead and made specific changes to the guidelines. As things stand right now, for secondary ASCVD, they came out and stated that the vast majority of patients with secondary ASCVD ought to be under 55. There's also another patient population within that group that could be under 70, but for most people dealing with secondary ASCVD, the target should be under 55, and that aligns with what's done in Europe and elsewhere around the globe. During the prepared remarks, I did mention that our efforts go beyond just pursuing an approval and a launch here in the U.S. — we're also engaged in regulatory discussions and review with the European Union, and with China too.

Caroline Litchfield

executive
#36

Building on what Rob and Dean said, the response we’ve gotten so far from important scientific leaders has been very strong, as they grasp the updated guidelines and see how this product can benefit patients. Our task now is to bring that over into primary care. Doing so will require a certain amount of time, but our sales teams will concentrate on making sure both primary care and patients receive proper education about why this medicine matters.

Peter Dannenbaum

executive
#37

Excellent. Jason, thanks. Let's take the next question.

Mohit Bansal

analyst
#38

I appreciate you taking my question. I'd like to ask about CD388, the flu drug program. Could you explain a bit about what led to the choice to include an additional Northern Hemisphere season? The key thing I'm wondering is whether that decision came from data you've already reviewed, or whether it was simply a matter of meeting regulatory requirements, as opposed to any diminished confidence in the results so far? Thank you.

Dean Li

executive
#39

I really appreciate that question. I want to point out that this antiviral is a first-in-class treatment, given once each season, and it works regardless of the strain — we're developing it to prevent flu, particularly in individuals who face elevated risk. Our consistent message has been that the launch is targeted for 2029, and alongside that, I had to complete CMC efforts so we could move from a three-shot regimen down to two shots. That piece is what constrains our timeline. I also stated that during the period leading up to then, my goal would be to secure the strongest possible label and the most solid packages, which would let us expand our network of sites to back a worldwide registration and position me to establish the proper value proposition outside the U.S. geographies, particularly given the considerations that arise in an MFN era. Additionally, we introduced an important secondary measure—hospitalization from any cause—which, in my view, will prove essential to that effort. Lastly, as this work proceeds, we are gathering information across patient subgroups and the various viral variants circulating globally. I also stated plainly that an interim analysis was neither necessary for me nor something I would accept. I neither received nor reviewed any interim data. My goal is to get the greatest possible performance out of this molecule within my required schedule, so that I don't take any action that would put the 2029 launch date at risk, while still securing the strongest possible label along with solid real-world evidence, which health authorities will care about.

Rob Davis

executive
#40

To put everything together, our level of confidence remains exactly the same, and nothing in the data has altered that. What this comes down to is how strong the filing is, since we have the time available because that bridging study Dean brought up has to be done.

Peter Dannenbaum

executive
#41

Thank you, Mohit. Next question, please, Shirley.

Evan Seigerman

analyst
#42

Hello everyone, and I really appreciate you letting me ask something. One thing that's come up repeatedly on this call is that $70 billion figure for possible opportunity tied to the coming product wave. What would pose the greatest danger to hitting that amount? And on the flip side, over the last six months, which programs have made you feel more confident? Thanks a lot.

Rob Davis

executive
#43

Yes, thank you for asking. Clearly, from what we've observed, one source of confidence is that results are arriving sooner than we anticipated. Back in January when this came up, we pointed out that sac-TMT and I-DXd wouldn't produce readouts before 2027. Positive readouts have now come in for both of them. TULI delivered its readout ahead of our expectations. Things are progressing on every front. Standing here now, I have more confidence than I did in January, since we're witnessing substantial de-risking. If you remember, we noted then that 10 programs accounted for 70% of that $70 billion. Given that a large share of them already show positive data—meaning we're de-risking them clinically—and given the solid launches among those already underway, such as LIPFENDRA launching several months early, it's honestly difficult to identify anything that concerns me. Across the board, I'm feeling pretty bullish. I should knock on wood, since everything is going well. That's a credit to our scientific team and to how strong the clinical studies are that we set up. I'm feeling really good about our position.

Peter Dannenbaum

executive
#44

Thanks, Evan. Let's take the next question.

Asad Haider

analyst
#45

Thanks for taking my question. This one's maybe for Dean, regarding the PD-1 VEGF bispecific program — any news on how quickly that development is moving, and how do you view any possible read-across from the HARMONi-3 data from Summit that's coming up? Also, is there anything new on where things stand with possible combination trials involving the PD-1 VEGF and your ADC assets? And if I could squeeze in a quick follow-up about TL1A — I realize it's already been covered quite a bit, but I'd value any context or color you can offer on where things stand with evaluating combination approaches, since that seems to be the direction the IBD field is heading. What's your take on TL1A when used alone — how well can it compete with the combination studies that J&J and AbbVie are pushing so hard on? Thanks.

Dean Li

executive
#46

Yeah, thanks so much. When it comes to the PD-1 and VEGF situation, my view is that plenty of data exists showing where PD-1 works; we've got 44 ourselves, and others have their own sets. That's one piece. On top of that, there's evidence indicating where VEGF works too. Once you examine where those two intersect, that's the area you'd target initially. Beyond that, certain tumors give us a chance to pair proprietary compounds that we already know have activity. Our attention will go toward PD-1 VEGF across those three overlapping areas where only we can advance. Following the Summit Akeso results is something we're quite eager to do. For us, that data matters. Broadly speaking, this captures how we approach PD-1 VEGF alongside PD-1 — targeting places where VEGF works and where our own known-active compounds could be paired. As for combining treatments, you've got it exactly right. Everyone in immunology is exploring ways to move toward combo treatments. Combinations have been tried many times before. With TNF and IL-23, there's data suggesting that pairing could matter. As for TL1A, our aim is for it to be among the most effective anti-cytokines—perhaps the most effective—in any indication we pursue. Another key point, in our view, is that its safety profile is very clean, and that opens the door to combination use. When you're thinking about pairing agents, the approach in IBD isn't going to match what you'd choose for HS, and both of those differ from a rheumatoid arthritis strategy. So for every one of these indications, we're evaluating how our TL1A performs and figuring out which partner therapy makes the most sense there.

Peter Dannenbaum

executive
#47

Great. Thank you, Asad. Next question, please.

Luisa Hector

analyst
#48

Hi there. I appreciate you taking my question. This one is also about LIPFENDRA, if I may. Regarding the particular language used on the label, which mentions LDL reduction, and then notes that cardiovascular outcomes trials have demonstrated that lowering LDL likewise results in fewer events, specifically in the case of monoclonal antibody PCSK9 inhibitors. I just wanted to verify if that language helps or hurts when you're talking with payers and when you're carrying out your promotional efforts. Staying with the CVOT subject, when is your LIPFENDRA CVOT scheduled, and could you say something about how you can guarantee that a decline in incretin use for weight loss won't affect the outcome? If that does occur, would you anticipate it to be balanced between the arms? Thanks.

Dean Li

executive
#49

I'll take that question. I have to be somewhat cautious when discussing what the FDA intended by including whatever note they included in the label. My view is it will be very helpful. Our belief is that LIPFENDRA ought to be given in addition to statins. I think that point matters a great deal. We also understand that the agency grasped that the design principles behind LIPFENDRA were shaped by the two antibodies already on the market. From a commercial perspective, I think it may prove useful, but I believe that was how the FDA and we, the conversation went. I want to stress that at present we do not have a CVOT, and there is a trial underway that is expected to report in 2029.

Peter Dannenbaum

executive
#50

Alright, thanks, Luisa — that's where we'll wrap things up. I realize another peer call is scheduled to begin shortly, so I appreciate everyone giving us your time and focus today. We're grateful for it. We hope to reconnect whenever it works best for you.

Operator

operator
#51

Appreciate it — that brings today’s call to a close. Thanks for taking part. You’re free to hang up at this point.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Merck & Co., Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Merck & Co., Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Merck & Co., Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.